600 cancer patients to help unlock secrets of immunotherapy success

NCT ID NCT07427186

Not yet recruiting Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 600 people with early-stage solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy before surgery. Researchers will collect blood and tumor samples at several time points to see how the immune system responds. The goal is to find biological markers that show whether the treatment is working. Participants will be monitored for up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which early-stage cancer patients will benefit most from immunotherapy before surgery.
What could go wrong: This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and results might not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer head and neck cancer melanoma non-small cell lung carcinoma urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID CANCERS

Contacts and locations

Locations

Chu Rangueil

Toulouse, 31400, France
Hopital Larrey

Toulouse, 31400, France
Institut Universitaire Du Cancer de Toulouse - Oncopole

Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.